Avadel Pharmaceuticals plc (AVDL) USD0.01

Sell:$8.00Buy:$8.25$0.21 (2.63%)

Prices delayed by at least 15 minutes
Sell:$8.00
Buy:$8.25
Change:$0.21 (2.63%)
Prices delayed by at least 15 minutes
Sell:$8.00
Buy:$8.25
Change:$0.21 (2.63%)
Prices delayed by at least 15 minutes

Company Information

About this company

Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's product, LUMRYZ, is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME and MEDUSA. Its MICROPUMP technology allows for the development of modified release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.

Key people

Gregory J. Divis
Chief Executive Officer, Director
Thomas S. Mchugh
Chief Financial Officer
Jerad Seurer
General Counsel and Corporate Secretary
Geoffrey M. Glass
Non-Executive Independent Chairman of the Board
Naseem Amin
Independent Director
Eric J. Ende
Independent Director
Mark Anthony Mccamish
Independent Director
Linda S. Palczuk
Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    Ireland
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    IE00BDGMC594
  • Market cap
    $768.00m
  • Employees
    154
  • Shares in issue
    96.36m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.